Comparative Pharmacology
Head-to-head clinical analysis: OGEN 625 versus OGEN 1 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 625 versus OGEN 1 25.
OGEN .625 vs OGEN 1.25
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
Treatment of moderate to severe vasomotor symptoms due to menopauseTreatment of vulvar and vaginal atrophy due to menopausePrevention of postmenopausal osteoporosis
Moderate to severe vasomotor symptoms due to menopauseVulvar and vaginal atrophyHypoestrogenism due to hypogonadism, castration, or primary ovarian failureOsteoporosis prevention (postmenopausal women)Palliative treatment of advanced breast cancer (off-label)Palliative treatment of advanced prostate cancer (off-label)
0.625 mg orally once daily
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
None Documented
None Documented
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days
Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized.
Hepatic metabolism via CYP3A4; undergoes enterohepatic recirculation; primarily excreted as conjugates in urine.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5%
~50-80% bound to sex hormone-binding globulin (SHBG) and albumin.
98–99% bound to albumin and sex hormone-binding globulin (SHBG)
Estrone: ~1-2 L/kg; indicates extensive tissue distribution.
Vd: 1.5–2.0 L/kg; distributes widely into tissues including breast, bone, and reproductive organs
Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption.
Oral: 30–50% due to first-pass metabolism; transdermal: 100%
No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min, use with caution
No specific dose adjustment provided; use with caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
No specific dose adjustment provided; use with caution in severe hepatic impairment.
Not indicated for use in pediatric patients
Not indicated for use in pediatric patients.
Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended
No specific dosage adjustment; initiate at the lowest effective dose and monitor for adverse effects.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women. Increased risk of breast cancer with combined estrogen-progestin therapy.
Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions.
["Cardiovascular disorders: increased risk of stroke, DVT, PE, MI","Malignant neoplasms: endometrial cancer (unopposed estrogen), breast cancer (with progestin)","Gallbladder disease, hypercalcemia","Hepatic impairment, cholestatic jaundice","Hereditary angioedema, hypothyroidism, elevated triglycerides","Retinal vascular thrombosis, fluid retention","Dementia (increased risk in women ≥65 years)"]
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
["Undiagnosed abnormal genital bleeding","Known or suspected estrogen-dependent neoplasia (e.g., breast cancer)","Active or history of venous thromboembolism (e.g., DVT, PE)","Active or history of arterial thromboembolism (e.g., stroke, MI)","Known protein C, protein S, or antithrombin deficiency","Known or suspected pregnancy","Severe hepatic impairment or disease"]
Data Pending Review
Data Pending Review
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions.
No specific food interactions; consistent intake of calcium and vitamin D recommended for bone health.
First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks.
Estropipate, an estrogen, increases risk of fetal harm, including congenital anomalies and urogenital tract abnormalities, especially with first-trimester exposure. Use is contraindicated in pregnancy. Second- and third-trimester exposure may cause feminization of male fetuses and long-term reproductive tract effects in females.
Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered.
Estrogens are excreted in human breast milk. Ogen 1.25 may suppress lactation and reduce milk production. Not recommended during breastfeeding. M/P ratio for estropipate is not established.
Estropipate is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant due to absolute contraindication. No dose adjustments are applicable as the drug should not be used.
Contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (e.g., increased clearance) do not alter this contraindication.
Category C
Category C
OGEN 0.625 mg (estropipate) is a conjugated estrogen tablet for hormone therapy. It may increase risk of endometrial cancer; use with progestin in women with intact uterus. Monitor for thromboembolic events. Not for prevention of cardiovascular disease or dementia. Avoid in pregnancy.
Start with lowest effective dose; monitor for endometrial hyperplasia if uterus intact; avoid use in pregnancy (Category X); consider transdermal route for venous thromboembolism risk.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately.Avoid smoking as it increases risk of blood clots.Inform all healthcare providers that you are taking estrogen.Regular breast exams and mammograms are recommended.
Take with food to reduce gastrointestinal upset.Notify prescriber if vaginal bleeding occurs.Do not take if pregnant or planning pregnancy.Report signs of blood clots (chest pain, leg swelling).